- Home
- RVPH vs INMB Comparison
RVPH vs INMB Comparison
Compare RVPH & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- INMB
- Stock Information
- Founded
- RVPH 2006
- INMB 2015
- Country
- RVPH United States
- INMB United States
- Employees
- RVPH N/A
- INMB N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- INMB Health Care
- Exchange
- RVPH Nasdaq
- INMB Nasdaq
- Market Cap
- RVPH 87.6M
- INMB 103.1M
- IPO Year
- RVPH N/A
- INMB 2019
- Fundamental
- Price
- RVPH $1.92
- INMB $8.30
- Analyst Decision
- RVPH Strong Buy
- INMB Strong Buy
- Analyst Count
- RVPH 5
- INMB 2
- Target Price
- RVPH $11.40
- INMB $21.00
- AVG Volume (30 Days)
- RVPH 3.0M
- INMB 405.9K
- Earning Date
- RVPH 11-14-2024
- INMB 10-31-2024
- Dividend Yield
- RVPH N/A
- INMB N/A
- EPS Growth
- RVPH N/A
- INMB N/A
- EPS
- RVPH N/A
- INMB N/A
- Revenue
- RVPH N/A
- INMB $42,000.00
- Revenue This Year
- RVPH N/A
- INMB N/A
- Revenue Next Year
- RVPH N/A
- INMB N/A
- P/E Ratio
- RVPH N/A
- INMB N/A
- Revenue Growth
- RVPH N/A
- INMB N/A
- 52 Week Low
- RVPH $0.60
- INMB $4.32
- 52 Week High
- RVPH $4.83
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- RVPH 52.37
- INMB 69.36
- Support Level
- RVPH $1.56
- INMB $6.04
- Resistance Level
- RVPH $2.06
- INMB $8.14
- Average True Range (ATR)
- RVPH 0.23
- INMB 0.63
- MACD
- RVPH -0.01
- INMB 0.24
- Stochastic Oscillator
- RVPH 52.46
- INMB 82.07
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.